![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Human Nutrition, University of Illinois at Chicago, Chicago, IL 60612
2To whom correspondence and reprint requests should be addressed. E-mail: adiamond{at}uic.edu.
Selenium is effective in reducing cancer incidence in animal models, and epidemiologic data, as well as supplementation trials, have indicated that selenium is likely to be effective in humans. The mechanism by which selenium prevents cancer remains unknown. The mammalian genome encodes 25 selenoprotein genes, each containing one or more molecules of selenium in the form of the amino acid selenocysteine, translationally inserted into the growing peptide in response to the UGA codon. There is evidence that several of these proteins may be involved with the mechanism by which selenium provides its anticancer effects. Data are reviewed indicating that genetic variants of the cytosolic glutathione peroxidase are associated with increased cancer risk, and that loss of one of the copies of this same gene may be involved with malignant progression. Similarly, allelic differences in the gene for a second selenoprotein, Sep15, may be relevant to the protection provided by selenium, and allelic loss at this locus have been reported as well. These data, along with the differential expression patterns reported for other selenoproteins in tumor vs. normal tissues, support the role of selenoproteins in the chemoprotection by selenium.
KEY WORDS: • selenium • selenoproteins • glutathione peroxidase • chemoprevention
This article has been cited by other articles:
|
|
 |
|
  P. Zhuo, M. Goldberg, L. Herman, B.-S. Lee, H. Wang, R. L. Brown, C. B. Foster, U. Peters, and A. M. Diamond Molecular Consequences of Genetic Variations in the Glutathione Peroxidase 1 Selenoenzyme Cancer Res., October 15, 2009; 69(20): 8183 - 8190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-A. Meyer, B. Hollenbach, C. Stephan, T. Endermann, N. G. Morgenthaler, H. Cammann, J. Kohrle, K. Jung, and L. Schomburg Reduced Serum Selenoprotein P Concentrations in German Prostate Cancer Patients Cancer Epidemiol. Biomarkers Prev., September 1, 2009; 18(9): 2386 - 2390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tarze, M. Dauplais, I. Grigoras, M. Lazard, N.-T. Ha-Duong, F. Barbier, S. Blanquet, and P. Plateau Extracellular Production of Hydrogen Selenide Accounts for Thiol-assisted Toxicity of Selenite against Saccharomyces cerevisiae J. Biol. Chem., March 23, 2007; 282(12): 8759 - 8767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Moghadaszadeh and A. H. Beggs Selenoproteins and Their Impact on Human Health Through Diverse Physiological Pathways. Physiology, October 1, 2006; 21(5): 307 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Diwadkar-Navsariwala, G. S. Prins, S. M. Swanson, L. A. Birch, V. H. Ray, S. Hedayat, D. L. Lantvit, and A. M. Diamond Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model PNAS, May 23, 2006; 103(21): 8179 - 8184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-H. Yoo, X.-M. Xu, B. A. Carlson, V. N. Gladyshev, and D. L. Hatfield Thioredoxin Reductase 1 Deficiency Reverses Tumor Phenotype and Tumorigenicity of Lung Carcinoma Cells J. Biol. Chem., May 12, 2006; 281(19): 13005 - 13008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Joshi, L. L. Johnson, W.-Q. Wei, C. C. Abnet, Z.-W. Dong, P. R. Taylor, P. J. Limburg, S. M. Dawsey, E. T. Hawk, Y.-L. Qiao, et al. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk chinese population. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 1046 - 1047. [Abstract] [Full Text] [PDF]
|
|
